Inaxaplin clinical trials
Also written VX-147.
How each study uses inaxaplin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
6 studies that test it; most in 2023 (2)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Studies
Open first, then newest update. How each study uses inaxaplin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney DiseaseActive, not recruitingPhase 2/3Vertex Pharmaceuticals IncorporatedNCT05312879Written as VX-147
- Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without ComorbiditiesCompletedPhase 2Vertex Pharmaceuticals IncorporatedNCT06794996Written as Inaxaplin
- Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental GlomerulosclerosisCompletedPhase 2Vertex Pharmaceuticals IncorporatedNCT04340362Written as VX-147
- Evaluation of the Pharmacokinetics and Safety of Inaxaplin in Participants With Mild or Moderate Hepatic ImpairmentCompletedPhase 1Vertex Pharmaceuticals IncorporatedNCT06529796Written as IXP
- A Study to Evaluate Pharmacokinetics (PK) and Safety of Inaxaplin in Participants With Renal ImpairmentCompletedPhase 1Vertex Pharmaceuticals IncorporatedNCT05865171Written as IXP
- A Study Evaluating the Relative Bioavailability and Food Effect of a Tablet Formulation of VX-147CompletedPhase 1Vertex Pharmaceuticals IncorporatedNCT05955872Written as VX-147
Codes
What other systems call inaxaplin · ClinicalTrials.gg INT017846
- UNII (FDA) S2SJ2RVZ6YINAXAPLINConfirmed FDA, Wikidata
- Wikidata Q123913944inaxaplinConfirmed FDA, Wikidata
- NCI Thesaurus C184889InaxaplinOne source FDA
- DrugBank DB21521One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | S2SJ2RVZ6Y | INAXAPLIN | Confirmed FDA, Wikidata |
| Wikidata | Q123913944 | inaxaplin | Confirmed FDA, Wikidata |
| NCI Thesaurus | C184889 | Inaxaplin | One source FDA |
| DrugBank | DB21521 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.